AM3701 / Amura - LARVOL DELTA

Enthusiastic Response to Novel Therapies on the Horizon in Multiple Myeloma (THE ASCO POST) - "Melflufen is a first-in-class peptide-conjugated alkylating agent that targets aminopeptidases, which are abundant in myeloma. It is a melphalan prodrug that is rapidly taken up by myeloma cells and hydrolyzed to release an alkylator payload. 'The idea is to get a better therapeutic index with this drug,' Dr. Anderson said."

Media quote